Psychopharmacologic Approaches to Treatment of Psychopathology
Author’s Name
Department/University
Course number
Course name
Instructor’s Name
, Psychopharmacologic Approaches to Treatment of Psychopathology
Introduction
Adverse outcomes can result from polypharmacy and the concurrent use of potentially
inappropriate drugs, especially in patient populations that are already at risk. Using evidence-
based, peer-reviewed literature as a guide, this post will examine the de-prescribing concerns for
four different patient scenarios and offer thorough recommendations.
Patient 1
The first patient is a 36-year-old man who is on long-term opioid treatment for chronic
pain and concurrent clonazepam for panic attacks and "relaxation." The main issues center on the
serious dangers of mixing benzodiazepines with opioids, such as an increased risk of respiratory
depression, overdose, and death (Garg et al., 2017). By concealing the underlying ailment,
benzodiazepines may exacerbate chronic pain while producing a deceptive impression of
"relaxation" (Henssler et al., 2022). Additionally, prolonged benzodiazepine use can result in
tolerance, dependency, and withdrawal symptoms when stopped (Longo & Johnson, 2000).
We would first inform the patient about the risks associated with mixing benzodiazepines
and opioids to allay these worries. We would emphasize how crucial it is to taper the clonazepam
cautiously to prevent any withdrawal symptoms, given the elevated danger of overdose and
mortality. With symptoms ranging from anxiety and irritability to more severe manifestations
including seizures and psychosis, withdrawal from benzodiazepines can be difficult (Baandrup,
2016).
We would advise switching the patient to a comparable long-acting benzodiazepine, like
diazepam, and then gradually lowering the dosage over weeks to months, contingent on the
Author’s Name
Department/University
Course number
Course name
Instructor’s Name
, Psychopharmacologic Approaches to Treatment of Psychopathology
Introduction
Adverse outcomes can result from polypharmacy and the concurrent use of potentially
inappropriate drugs, especially in patient populations that are already at risk. Using evidence-
based, peer-reviewed literature as a guide, this post will examine the de-prescribing concerns for
four different patient scenarios and offer thorough recommendations.
Patient 1
The first patient is a 36-year-old man who is on long-term opioid treatment for chronic
pain and concurrent clonazepam for panic attacks and "relaxation." The main issues center on the
serious dangers of mixing benzodiazepines with opioids, such as an increased risk of respiratory
depression, overdose, and death (Garg et al., 2017). By concealing the underlying ailment,
benzodiazepines may exacerbate chronic pain while producing a deceptive impression of
"relaxation" (Henssler et al., 2022). Additionally, prolonged benzodiazepine use can result in
tolerance, dependency, and withdrawal symptoms when stopped (Longo & Johnson, 2000).
We would first inform the patient about the risks associated with mixing benzodiazepines
and opioids to allay these worries. We would emphasize how crucial it is to taper the clonazepam
cautiously to prevent any withdrawal symptoms, given the elevated danger of overdose and
mortality. With symptoms ranging from anxiety and irritability to more severe manifestations
including seizures and psychosis, withdrawal from benzodiazepines can be difficult (Baandrup,
2016).
We would advise switching the patient to a comparable long-acting benzodiazepine, like
diazepam, and then gradually lowering the dosage over weeks to months, contingent on the
